Cabaletta Bio, a clinical-stage biopharmaceutical company focused on autoimmune diseases, is currently trading 40% below its $2.41 pipeline value. Its lead CAR T therapy, rese-cel, targets severe autoimmune conditions with pivotal Phase 1/2 data expected by mid-2027 and a Biologics License Application submission planned for late 2027. A recent 10-year manufacturing agreement with Cellares is expected to reduce future costs of goods sold, supporting margin expansion if rese-cel gains approval. Despite potential dilution, the company's risk-adjusted fair value remains 57% above current prices, indicating a strong margin of safety for investors.
Cabaletta Bio faces a 40% sell-off relative to its $2.41 pipeline value, highlighting notable market volatility. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 13, 2026 18:43 WIB: out of 128 priced US health-sector stocks, 76 rose and 46 fell. Notable movers include Aurora Cannabis Inc (ACB) at USD 4.25 with 100% sell order activity, Summit Therapeutics Inc (SMMT) at USD 16.75 with 97% buy order activity, and Incyte Corporation (INCY) at USD 109.38 with 100% buy order activity and a typical hold time of 33 days.
Existing-home sales in the U.S. increased by 1.5% month-over-month in September but declined 2.2% compared to the previous year, according to the National Association of Realtors. Sales rose in the South and West regions but fell in the Northeast and...
Columbus Marketing Experts, a digital marketing agency in Hilliard, Ohio, is expanding its local SEO services across Columbus to help service businesses improve their visibility on Google Search and Google Maps. The expansion aims to enhance local di...
Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Nvidia CEO Jensen Huang has reaffirmed his forecast that global spending on AI infrastructure will grow significantly, reaching between $3 trillion and $4 trillion by 2030. This projection highlights the massive potential and ongoing investment in AI...
